Clinical Trial Update: A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluates enzalutamide combined with relacorilant versus placebo for patients with high-risk localized prostate cancer and is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Relacorilant (relacorilant)
• Xtandi (enzalutamide)

Snippet

Sponsor: University of Chicago | Conditions: Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING